Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 15/20 | 1.00 |
| ▸ | PPARG | P37231 | 13/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | USP1 | O94782 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100299 | 0.99 | PPARA (0.98) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL6552622 | 0.89 | PPARA (0.80) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL4265257 | 0.87 | PPARA (1.00) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL16147204 | 0.83 | PPARA (1.00) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL6552333 | 0.83 | PPARA (0.73) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL16147851 | 0.82 | PPARA (1.00) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL16147225 | 0.81 | PPARA (1.00) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL12274271 | 0.80 | PPARA (0.67) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL21123888 | 0.80 | PPARA (0.67) | PPARAPPARGPPARDGMNNUSP2 | |
| SCHEMBL3675079 | 0.79 | PPARA (0.65) | PPARAPPARGPPARDGMNNUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 815 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| US-20250297321-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | claimed |
| EP-4583859-A2 | COMPOSITIONS FOR PREVENTING TRANSITION FROM ACUTE TO CHRONIC PAIN | The Regents of University of California (US) | 2025-07-16 | — | — | EP | claimed |
| EP-4558622-A1 | METHODS AND COMPOSITIONS FOR GENERATING HUMAN MIDBRAIN DOPAMINERGIC NEURONS FROM NEURAL PROGENITOR CELLS | Trailhead Biosystems Inc. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-120051560-A | Methods and compositions for generating human midbrain dopaminergic neurons from neural progenitor cells | 特雷尔赫德生物系统股份有限公司 | 2025-05-27 | — | — | CN | claimed |
| CN-120004949-A | Mitochondria targeting compound, preparation method and application thereof, and pharmaceutical composition | 中国医学科学院医药生物技术研究所 | 2025-05-16 | — | — | CN | claimed |
| CN-119235836-A | Application of GW7647 in preparation of medicine for inhibiting cell lipid peroxidation caused by African swine fever virus protein | 华中农业大学 | 2025-01-03 | — | — | CN | claimed |
| US-20240398789-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ANTI-TUMOR EFFECT OF EZH2 INHIBITOR AND USE THEREOF | PEKING UNIVERSITY THIRD HOSPITAL (CN) | 2024-12-05 | — | — | US | claimed |
| EP-4469602-A1 | METHOD FOR DETECTING METABOLIC REPROGRAMING OF CANCER TOWARDS FATTY ACIDS METABOLISM | Université Paris Cité (FR) | 2024-12-04 | — | — | EP | claimed |
| US-20240285540-A1 | FUNCTIONAL THERAPEUTIC INDEX IN THE TREATMENT OF PERIPHERAL IMMUNE DYSFUNCTION | MASCARENHAS DESMOND (US) | 2024-08-29 | — | — | US | claimed |
| EP-1569640-A4 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | claimed |
| EP-1569640-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | claimed |
| US-20050054730-A1 | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-03-10 | — | — | US | claimed |
| WO-2005002524-A2 | COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-01-13 | — | — | WO | claimed |
| EP-1149063-B1 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-12-15 | — | — | EP | claimed |
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | US | claimed |
| WO-2003059294-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1149063-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2001-10-31 | — | — | EP | claimed |
| US-6306854-B1 | ARYLTHIOALKYLACIDS AND ALKYL UREAS | GLAXOSMITHKLINE | 2001-10-23 | — | — | US | claimed |
| WO-2000023407-A2 | UREIDO-THIOBUTYRIC ACID DERIVATIVES AS PPAR-AGONISTS | GLAXO GROUP LIMITED (GB) | 2000-04-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212138-A1 | Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor | PPARG, PPARA, PPARD | PPARA 2/4885PPARG 1/4885PPARD 3/4885 |
| US-20050054730-A1 | Compounds, compositions and treatment of oleoylethanolamide-like modulators of PPARalpha | PPARA, CNR2, CNR1 | PPARA 1/4885PPARG 11/4885PPARD 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.